<DOC>
	<DOCNO>NCT00109564</DOCNO>
	<brief_summary>The purpose Phase II study evaluate efficacy safety ispronicline ( TC-1734-112 ) compare placebo ( inactive substance pill ) patient age associate memory impairment ( AAMI ) . AAMI characterize cognitive impairment include memory loss poor concentration associate age .</brief_summary>
	<brief_title>A Safety Efficacy Study Ispronicline ( TC-1734-112 ) Subjects With Age Associated Memory Impairment ( AAMI )</brief_title>
	<detailed_description />
	<mesh_term>Memory Disorders</mesh_term>
	<mesh_term>Nicotinic Agonists</mesh_term>
	<mesh_term>Acetylcholine</mesh_term>
	<criteria>Male female subject age 5080 year . Lives significant . Has subjective memory complaint . Verbal verification subjective memory complaint obtain significant . Has severe , uncontrolled medical condition . If receive treatment medical condition , treatment stable least 2 month enter trial remain stable throughout trial . Exclusion Criteria Aged le 50 year great 80 year . Lives alone . Has medical condition adequately control , likely interfere performance study procedure . Medication medical condition change last 2 month trial . Administration acetylcholinesterase inhibitor gingko biloba within 2 month prior enter study . Has evidence depression anxiety Meets DSMIV criterion Alzheimer 's vascular dementia . Has participate investigational drug trial previous 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>AAMI</keyword>
	<keyword>Memory Impairment</keyword>
	<keyword>Decline Cognitive Function</keyword>
	<keyword>Age Associated Memory Impairment</keyword>
</DOC>